Scalable xeno-free manufacturing of extracellular vesicles derived from human mesenchymal stem cells

Having been investigated in >800 clinical trials without significant adverse events, human mesenchymal stem cells (hMSCs) are a safe and clinically relevant cell source for producing extracellular vesicles (EVs) such as exosomes. Not only can hMSC-EVs deliver exogenous agents including RNA and proteins, hMSC-EVs also inherit the therapeutic potential of hMSCs and have been applied in >20 disease models. However, based on the current state of the art, a single hMSC-EV dose would require an equivalent of >10 hMSC doses to generate, rendering this technology cost-prohibitive.